Company brings together world-class industry experts and enterprise
cloud software innovators to address customers’ most strategic
challenges in clinical trials
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that it has expanded its
leadership team across product management and cloud software development
to accelerate innovation and customer success in clinical operations and
data management. Veeva is bringing together established industry experts
with proven cloud innovators to continue to deliver clinical
applications that will unify end-to-end processes and help speed trials.
“We have a significant opportunity to help the industry overcome current
limitations and better manage the complexity of global trials,” said
Peter Gassner, founder and CEO of Veeva Systems. “We’re deepening the
bench on our world-class clinical team with talented leaders that bring
strong technology and life sciences background to Veeva. Our balance of
industry expertise and cloud software knowledge puts us in a unique
position to be a strategic partner to life sciences.”
In addition to its expanded clinical team, Veeva today introduced Veeva
Vault EDC and Veeva
Vault eSource, the first applications on a single cloud platform to
provide a better, modern approach for clinical data management. In less
than four years, Veeva has added more than 120 clinical operations
customers, including global deployments of Veeva
Vault eTMF at seven of the top 20 pharma companies. The company is
building upon this success by adding to its talented clinical team and
delivering new applications as part of the Veeva
Vault Clinical Suite that will drive
the next phase of innovation in clinical trials.
The members of Veeva’s expanded clinical team will now include:
-
Henry
Levy, chief strategy officer – Levy has nearly 25 years of
experience transforming the way the biopharmaceutical industry
improves patient health. He leads Veeva’s market strategy and
strategic relationships with customers and partners in multiple areas,
including clinical. Levy also represents Veeva in various industry
collaborations. Previously, he ran client development and commercial
services at PPD, one of the world’s largest CROs, and was head of
Accenture’s global life sciences R&D practice.
-
Jill
Johnston, vice president, Veeva Vault Clinical – Johnston
is responsible for leading the development of Veeva’s clinical
operations products and market strategy. She has more than
20 years of expertise in clinical operations, pharmaceutical
efficiency, and transformation initiatives across Phase I-IV. Prior to
Veeva, she held a variety of senior leadership roles in clinical
operations, project management, and Six Sigma at Covance, a leading
global CRO.
-
Brian
Longo, senior vice president and general manager, Veeva Vault EDC –
Over the past 10 years at Veeva, Longo has architected and
innovated industry-specific cloud solutions for drug discovery,
medical affairs, and commercial. He leads the development of Vault EDC
and Vault eSource, delivering the technology innovation that customers
need to improve speed and data quality and cut the cost and complexity
in clinical trials.
-
Richard
Young, vice president, Veeva Vault EDC – Young has nearly
25 years of expertise in data management, clinical solutions, and
advanced clinical strategies. His broad experience in life sciences
includes roles at Medidata where he focused on adaptive trials,
risk-based monitoring, mHealth, and big data, as well as operational
roles at leading pharma and CRO organizations, including
GlaxoWellcome, Novo Nordisk, and PAREXEL. At Veeva, Young is
establishing Vault EDC as the leading solution for clinical data
management.
-
Drew
Garty, vice president, product management, Veeva Vault EDC –
Garty’s career in pharmaceutical technology spans nearly 20 years and
includes extensive experience in clinical system architecture, design,
and development, including EDC. He is responsible for developing and
implementing innovative technology solutions as part of the Veeva
Vault Clinical Suite, including Vault EDC and Vault eSource. Prior to
Veeva, he spent the majority of his career at PAREXEL where he led the
institutionalization of EDC and development of innovative solutions
such as risk-based monitoring.
-
Michelle
Marlborough, vice president, product management, Veeva Vault CTMS
– In her role, Marlborough is responsible for the development of Veeva
Vault CTMS. She brings 20 years of experience to Veeva
transforming clinical trials through innovative technology and
analytics. Before Veeva, Marlborough was vice president of product
strategy at Medidata and held data management roles at leading
pharmaceutical companies, including GSK and AstraZeneca.
For more about Veeva transforming clinical data management, read our press
release to learn how Vault EDC and Vault eSource will deliver
real-time, accurate data and help enable faster, more informed decisions
in clinical trials.
Availability
Veeva Vault EDC is expected to be available in April 2017, while Veeva
Vault eSource is expected to be available in December 2017.
Connect with the Veeva clinical team on LinkedIn:
Henry
Levy
Jill
Johnston
Brian
Longo
Richard
Young
Drew
Garty
Michelle
Marlborough
Additional Veeva Information:
For more on Veeva Vault EDC, visit: veeva.com/VaultEDC
For
more on Veeva Vault eSource, visit: veeva.com/VaulteSource
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
us @veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 450 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended July 31, 2016. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
® 2016 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo
are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other
registered and unregistered trademarks.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161013005494/en/
Source: Veeva Systems Inc.